The stock has a 36-month beta value of 0.52. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CMMB is 16.57M, and at present, short sellers hold a 0.18% of that float. On March 10, 2025, the average trading volume of CMMB was 361.54K shares.
CMMB) stock’s latest price update
Chemomab Therapeutics Ltd ADR (NASDAQ: CMMB)’s stock price has dropped by -15.54 in relation to previous closing price of 1.48. Nevertheless, the company has seen a loss of -25.60% in its stock price over the last five trading days. globenewswire.com reported 2025-03-06 that Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL AVIV, Israel, March 06, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics, Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced a new scientific presentation that further confirms the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis (SSc).1 The data will be presented at the 8th International Congress on Controversies in Rheumatology and Autoimmunity (CORA 2025) on March 8, 2025, in Venice, Italy.
CMMB’s Market Performance
Chemomab Therapeutics Ltd ADR (CMMB) has seen a -25.60% fall in stock performance for the week, with a -39.90% decline in the past month and a -27.75% plunge in the past quarter. The volatility ratio for the week is 15.33%, and the volatility levels for the past 30 days are at 10.49% for CMMB. The simple moving average for the past 20 days is -27.03% for CMMB’s stock, with a -17.59% simple moving average for the past 200 days.
Analysts’ Opinion of CMMB
Many brokerage firms have already submitted their reports for CMMB stocks, with Maxim Group repeating the rating for CMMB by listing it as a “Buy.” The predicted price for CMMB in the upcoming period, according to Maxim Group is $4 based on the research report published on May 13, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CMMB reach a price target of $6. The rating they have provided for CMMB stocks is “Outperform” according to the report published on May 06th, 2024.
ROTH MKM gave a rating of “Buy” to CMMB, setting the target price at $7 in the report published on December 19th of the previous year.
CMMB Trading at -34.74% from the 50-Day Moving Average
After a stumble in the market that brought CMMB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.98% of loss for the given period.
Volatility was left at 10.49%, however, over the last 30 days, the volatility rate increased by 15.33%, as shares sank -40.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -25.60% lower at present.
During the last 5 trading sessions, CMMB fell by -25.60%, which changed the moving average for the period of 200-days by +48.63% in comparison to the 20-day moving average, which settled at $1.7131. In addition, Chemomab Therapeutics Ltd ADR saw -30.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CMMB starting from OrbiMed Israel Partners Limite, who proposed sale 500,000 shares at the price of $2.03 back on Sep 12 ’24. After this action, OrbiMed Israel Partners Limite now owns shares of Chemomab Therapeutics Ltd ADR, valued at $1,015,000 using the latest closing price.
Stock Fundamentals for CMMB
The total capital return value is set at -0.93. Equity return is now at value -91.76, with -71.63 for asset returns.
Based on Chemomab Therapeutics Ltd ADR (CMMB), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -26.41. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -7745.8.
Currently, EBITDA for the company is -25.39 million with net debt to EBITDA at 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.98.
Conclusion
To sum up, Chemomab Therapeutics Ltd ADR (CMMB) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
